The past decade has seen little by way of new treatment for epilepsy, and existing medications can come with significant adverse reactions. Given this, biopharmaceutical companies need to take a different course to improve treatments for people with seizure disorders. For many developers, taking a rare-disease approach may be the answer.
Read MoreIn the world of academic technology development, there is a small pool of academic centers reaping most of the benefit from industry partnering. Back Bay Life Science Advisors analyzed the partnering landscape to offer solutions to increase productivity and investment returns.
Read MoreBack Bay Life Science Advisors analyzed companies involved in neoantigen therapy development. Our white paper explores the promise of neoantigens to eliminate specific tumor types, and highlights some of the companies driving a groundswell of emerging therapeutics that harness a neoantigen approach.
Read MoreMedical device companies developing next-generation mitral valve repair and replacement technologies have generated unprecedentedly high valuations at ever-earlier stages of device development. MedTech investors are acquiring early-stage transcatheter mitral valve technologies long before commercialization and even before critical clinical data is amassed.
Read MoreFor nearly a decade, biosimilars have loomed large over every facet of the US healthcare debate. Depending on where you sit, biosimilars represent either a dreaded threat to innovation or a hoped-for answer to sky-high drug prices. However, neither scenario has fully come to pass, and although we still expect biosimilars to effect change in the biologics market, when it will happen and to what degree are still unknown.
Read More
